Regulatory milestones

Actelion Ltd. (SIX:ATLN) was down CHF1.34 to CHF44.99 on Friday after announcing FDA accepted for review an NDA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). A decision is expected around October 2013; the exact PDUFA date is not disclosed. Last week, the stock was down CHF1.81.